FY2025 EPS Forecast for DarioHealth Lowered by Analyst

DarioHealth Corp. (NASDAQ:DRIO) – Equities research analysts at Litchfield Hills Research lowered their FY2025 EPS estimates for DarioHealth in a research report issued to clients and investors on Thursday, January 22nd. Litchfield Hills Research analyst T. O’neill now expects that the company will earn ($12.36) per share for the year, down from their previous estimate of ($12.34). The consensus estimate for DarioHealth’s current full-year earnings is ($1.18) per share. Litchfield Hills Research also issued estimates for DarioHealth’s Q4 2025 earnings at ($1.80) EPS, Q1 2026 earnings at ($1.31) EPS, Q2 2026 earnings at ($1.11) EPS, Q3 2026 earnings at ($0.85) EPS, Q4 2026 earnings at ($0.62) EPS and FY2026 earnings at ($4.00) EPS.

Several other equities research analysts also recently weighed in on DRIO. TD Cowen reaffirmed a “hold” rating on shares of DarioHealth in a report on Friday, November 14th. Wall Street Zen downgraded shares of DarioHealth from a “hold” rating to a “sell” rating in a research report on Sunday. Stifel Nicolaus set a $16.00 target price on shares of DarioHealth in a research note on Friday, November 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DarioHealth in a report on Monday, December 29th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $32.00.

DarioHealth Stock Down 0.8%

DarioHealth stock opened at $11.64 on Monday. The stock has a 50 day moving average of $11.99 and a two-hundred day moving average of $11.98. DarioHealth has a twelve month low of $5.93 and a twelve month high of $17.74. The stock has a market capitalization of $78.69 million, a price-to-earnings ratio of -1.04 and a beta of 1.05. The company has a current ratio of 4.55, a quick ratio of 4.02 and a debt-to-equity ratio of 0.41.

Institutional Investors Weigh In On DarioHealth

An institutional investor recently raised its position in DarioHealth stock. XTX Topco Ltd increased its position in shares of DarioHealth Corp. (NASDAQ:DRIO) by 229.0% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 62,511 shares of the company’s stock after purchasing an additional 43,513 shares during the quarter. XTX Topco Ltd owned 0.14% of DarioHealth worth $42,000 as of its most recent filing with the SEC. 33.39% of the stock is currently owned by institutional investors and hedge funds.

About DarioHealth

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.